Skip to content

Reported March 6, 2026 · Before market open

Next report

Aug 12, 2026 (in 2 months)
EPS estimate-$0.66

Financials

Q4 2025

Income statement

See full
Operating income-$35.0M+1.6%
Net income-$31.9M+32.0%
EPS (diluted)-$0.11+99.3%

Balance sheet

See full
Cash & equivalents$88.4M+27.5%
Total debt$851.0K+104%
Total equity$332.5M+811%
Total assets$349.8M+380%

Cash flow

See full
Operating cash flow-$33.6M-48.8%
CapEx$3.0K
Free cash flow-$33.7M

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$760.92M
Enterprise value$673.33M

Returns & leverage

See full
Debt / equity
Current ratio21.1×+15.3×

Versus estimates

Ask the moment Jade Biosciences, Inc. Common Stock reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Jade Biosciences, Inc. Common Stock report Q4 2025 earnings?
Jade Biosciences, Inc. Common Stock (JBIO) reported Q4 2025 earnings on March 6, 2026 before market open.
What were Jade Biosciences, Inc. Common Stock's Q4 2025 revenue and EPS?
Jade Biosciences, Inc. Common Stock reported diluted EPS of $-0.11 for Q4 2025.
Did Jade Biosciences, Inc. Common Stock beat estimates in Q4 2025?
EPS beat the consensus estimate of $-0.45 by $0.34.
How did Jade Biosciences, Inc. Common Stock's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS grew 42.1% from $-0.19.
Where can I find Jade Biosciences, Inc. Common Stock's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-094967) and the 10-K periodic report (0001193125-26-096550) directly on SEC EDGAR. The filing index links above go to sec.gov.